PMID- 25874259
OWN - NLM
STAT- MEDLINE
DCOM- 20160712
LR  - 20181113
IS  - 1537-744X (Electronic)
IS  - 2356-6140 (Print)
IS  - 1537-744X (Linking)
VI  - 2015
DP  - 2015
TI  - Theragnostic imaging using radiolabeled antibodies and tyrosine kinase 
      inhibitors.
PG  - 842101
LID - 10.1155/2015/842101 [doi]
LID - 842101
AB  - During the past decade, the efficacy of new molecular targeted drugs such as 
      tyrosine kinase inhibitors (TKIs) and monoclonal antibodies has been proven 
      worldwide, and molecular targeted therapies have become the mainstream in cancer 
      therapy. However, clinical use of these new drugs presents unexpected adverse 
      effects or poor therapeutic effects. Therefore, we require diagnostic tools to 
      estimate the target molecule status in cancer tissues and predict therapeutic 
      efficacy and adverse effects. Although immunohistochemical, polymerase chain 
      reaction (PCR) and fluorescence in situ hybridization (FISH) analyses of biopsy 
      samples are conventional and popular for this diagnostic purpose, molecular 
      imaging modalities such as positron emission tomography (PET) and single photon 
      emission computed tomography (SPECT) are also useful for noninvasive estimation 
      of gene and protein expression and drug pharmacokinetics. In this review, we 
      introduce new radiolabeled TKIs, antibodies, and their clinical application in 
      molecular targeted therapy and discuss the issues of these imaging probes.
FAU - Yoshimoto, Mitsuyoshi
AU  - Yoshimoto M
AUID- ORCID: 0000-0003-2083-9148
AD  - Division of Functional Imaging, National Cancer Center Hospital East, 6-5-1, 
      Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
FAU - Kurihara, Hiroaki
AU  - Kurihara H
AD  - Diagnostic Radiology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, 
      Tokyo 104-0045, Japan.
FAU - Fujii, Hirofumi
AU  - Fujii H
AD  - Division of Functional Imaging, National Cancer Center Hospital East, 6-5-1, 
      Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150322
PL  - United States
TA  - ScientificWorldJournal
JT  - TheScientificWorldJournal
JID - 101131163
RN  - 0 (Antibodies)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Radiopharmaceuticals)
SB  - IM
MH  - Antibodies/*pharmacology
MH  - *Diagnostic Imaging
MH  - Humans
MH  - Mutation/genetics
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Radiopharmaceuticals/*pharmacology
MH  - Theranostic Nanomedicine/*methods
PMC - PMC4385703
EDAT- 2015/04/16 06:00
MHDA- 2016/07/13 06:00
PMCR- 2015/03/22
CRDT- 2015/04/16 06:00
PHST- 2014/06/23 00:00 [received]
PHST- 2014/08/22 00:00 [revised]
PHST- 2014/08/22 00:00 [accepted]
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2016/07/13 06:00 [medline]
PHST- 2015/03/22 00:00 [pmc-release]
AID - 10.1155/2015/842101 [doi]
PST - ppublish
SO  - ScientificWorldJournal. 2015;2015:842101. doi: 10.1155/2015/842101. Epub 2015 Mar 
      22.